pepgen inc - PEPG
PEPG
Close Chg Chg %
3.21 0.02 0.47%
Open Market
3.23
+0.02 (0.47%)
Volume: 572.47K
Last Updated:
Sep 9, 2026, 12:55 PM EDT
Company Overview: pepgen inc - PEPG
PEPG Key Data
| Open $3.17 | Day Range 3.17 - 3.48 |
| 52 Week Range 1.31 - 7.80 | Market Cap $215.40M |
| Shares Outstanding 69.26M | Public Float 61.79M |
| Beta 1.97 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.31 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 782.16K |
PEPG Performance
| 1 Week | 0.00% | ||
| 1 Month | 9.12% | ||
| 3 Months | 111.56% | ||
| 1 Year | 110.14% | ||
| 5 Years | N/A |
PEPG Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About pepgen inc - PEPG
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded on November 9, 2020 and is headquartered in Boston, MA.
PEPG At a Glance
PepGen Inc.
321 Harrison Avenue
Boston, Massachusetts 02118
| Phone | 1-781-797-0979 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -89,655,000.00 | |
| Sector | Health Technology | Employees | 56 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PEPG Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.041 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.555 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.119 |
PEPG Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,600,982.143 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PEPG Liquidity
| Current Ratio | 11.938 |
| Quick Ratio | 11.938 |
| Cash Ratio | 11.739 |
PEPG Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -55.208 |
| Return on Equity | -67.394 |
| Return on Total Capital | -54.519 |
| Return on Invested Capital | -60.691 |
PEPG Capital Structure
| Total Debt to Total Equity | 11.533 |
| Total Debt to Total Capital | 10.34 |
| Total Debt to Total Assets | 9.778 |
| Long-Term Debt to Equity | 9.371 |
| Long-Term Debt to Total Capital | 8.402 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Pepgen Inc - PEPG
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 493.00K | 1.18M | 1.50M | 1.40M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 493.00K | 1.18M | 1.50M | 1.40M | |
Depreciation
| 493.00K | 1.18M | 1.50M | 1.40M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +176.97% | +140.16% | +27.11% | -7.18% | |
Gross Income
| (493.00K) | (1.18M) | (1.50M) | (1.40M) | |
Gross Income Growth
| -176.97% | -140.16% | -27.11% | +7.18% | |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 67.81M | 83.58M | 96.23M | 92.22M | |
Research & Development
| 53.58M | 66.94M | 74.97M | 69.65M | |
Other SG&A
| 14.22M | 16.64M | 21.26M | 22.57M | |
SGA Growth
| +151.78% | +23.26% | +15.14% | -4.18% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (68.30M) | (84.77M) | (97.74M) | (93.61M) | |
Non Operating Income/Expense
| 2.90M | 6.21M | 7.14M | 4.01M | |
Non-Operating Interest Income
| 2.79M | 6.40M | 7.14M | 4.02M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (65.40M) | (78.55M) | (90.60M) | (89.61M) | |
Pretax Income Growth
| -139.72% | -20.12% | -15.33% | +1.09% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| 3.71M | 73.00K | (617.00K) | 49.00K | |
Income Tax - Current - Domestic
| 23.00K | 73.00K | 84.00K | 49.00K | |
Income Tax - Current - Foreign
| - | - | 3.68M | (701.00K) | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (69.10M) | (78.63M) | (89.98M) | (89.66M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (69.10M) | (78.63M) | (89.98M) | (89.66M) | |
Net Income Growth
| -153.30% | -13.78% | -14.44% | +0.36% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (69.10M) | (78.63M) | (89.98M) | (89.66M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (69.10M) | (78.63M) | (89.98M) | (89.66M) | |
EPS (Basic)
| -2.9142 | -3.3042 | -2.849 | -2.1234 | |
EPS (Basic) Growth
| -139.20% | -13.38% | +13.78% | +25.47% | |
Basic Shares Outstanding
| 23.71M | 23.80M | 31.58M | 42.22M | |
EPS (Diluted)
| -2.9142 | -3.3042 | -2.849 | -2.1234 | |
EPS (Diluted) Growth
| -139.20% | -13.38% | +13.78% | +25.47% | |
Diluted Shares Outstanding
| 23.71M | 23.80M | 31.58M | 42.22M | |
EBITDA
| (67.81M) | (83.58M) | (96.23M) | (92.22M) | |
EBITDA Growth
| -151.78% | -23.26% | -15.14% | +4.18% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 10.188 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.266 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -1.062 | |
| Last Quarter’s Earnings | -0.26 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -2.12 | Next Fiscal Year Estimate | -1.089 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 8 | 8 |
| Mean Estimate | -0.27 | -0.29 | -1.06 | -1.09 |
| High Estimates | -0.22 | -0.21 | -0.97 | -0.73 |
| Low Estimate | -0.29 | -0.50 | -1.16 | -1.78 |
| Coefficient of Variance | -8.61 | -31.93 | -6.17 | -37.05 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Pepgen Inc - PEPG
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Pepgen Inc - PEPG
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 19, 2025 | Noel Donnelly Chief Financial Officer | 144,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 19, 2025 | Noel Donnelly Chief Financial Officer | 203,339 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 19, 2025 | Noel Donnelly Chief Financial Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 19, 2025 | Paul D. Streck EVP, Head of R&D | 242,816 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 19, 2025 | Paul D. Streck EVP, Head of R&D | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 19, 2025 | Paul D. Streck EVP, Head of R&D | 202,816 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 19, 2025 | Paul D. Streck EVP, Head of R&D | 40,000 | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | 300,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | 275,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | 466,095 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | 40,815 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | 40,815 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | 40,815 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 19, 2025 | James Gregg McArthur President and CEO; Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |